文献速递生殖医学

第7天囊胚临床结局的系统综述与荟萃分析

Clinical outcomes of Day-7 blastocysts: a systematic review and meta-analysis.
PubMed 文献 · Hum Reprod Update · 2026-07-22

该研究对比第7天与第5/6天冻融囊胚移植的临床妊娠率(CPR)和活产率(LBR)。纳入17项回顾性研究,第7天囊胚的CPR和LBR显著低于第5天和第6天,流产率(MR)高于第5天,整倍体率也降低;但围产结局总体令人安心。

要点

  • 第7天囊胚移植的CPR和LBR显著低于第5天和第6天囊胚。
  • 第7天囊胚的MR高于第5天囊胚,整倍体率也显著降低。
  • 围产结局数据有限但总体令人安心,仍需前瞻性研究验证。

核心结论

  • 尽管成功率较低,第7天囊胚仍可能对累积活产率有贡献,尤其对预后不良患者。

研究设计与样本

  • 系统综述与荟萃分析,纳入17项回顾性研究,截至2026年4月1日。

主要发现

  • 第7天移植共2908例;CPR对比第5天OR 0.26(95%CI 0.19-0.35,I2=76.2%,16项研究),LBR OR 0.23(95%CI 0.16-0.33,I2=76.3%,12项研究)。
  • 第7天vs第6天CPR OR 0.38(95%CI 0.31-0.48,I2=54.4%,16项研究),LBR OR 0.37(95%CI 0.28-0.49,I2=60.2%,12项研究)。
  • 第7天vs第5天MR OR 1.54(95%CI 1.04-2.30,I2=51.1%,14项研究)。
  • 仅PGT-A整倍体囊胚中,第7天vs第5天CPR OR 0.21(95%CI 0.14-0.33),LBR OR 0.21(95%CI 0.17-0.28),MR OR 2.78(95%CI 1.57-4.89)。
  • 第7天囊胚整倍体率显著低于第5天和第6天囊胚。

临床怎么用

  • 对预后不良患者可考虑移植第7天囊胚以增加累积活产机会,但需告知成功率较低。

局限性

  • 纳入研究均为回顾性,异质性低至高度,围产结局数据有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Extended embryo culture beyond Day-6 remains controversial. While a small subset of embryos reaches the blastocyst stage on Day-7, their developmental competence and reproductive potential remain uncertain. Data from previous studies have been limited and heterogeneous, particularly for meta-analytical evaluation of euploid embryo transfers. OBJECTIVE AND RATIONALE: This systematic review and meta-analysis compared clinical pregnancy (CPR) and live birth rates (LBR), as well as implantation (IR), miscarriage (MR), and ongoing pregnancy rates (OPR), between Day-7 frozen blastocysts and those obtained on Day-5 and/or Day-6. Euploidy rates by day of blastocyst development and available perinatal outcomes were also assessed. SEARCH METHODS: Conducted according to PRISMA guidelines, this review included full-length English-language human studies, published up to 1 April 2026, comparing frozen transfers of Day-7 versus Day-5/6 blastocysts and reporting at least clinical pregnancy and/or live birth outcomes. Random-effects models were used to estimate pooled odds ratios (ORs) with 95% confidence intervals (95% CI). Obstetric and perinatal outcomes were analysed when available. OUTCOMES: A total of 17 retrospective studies were included. Across 2908 Day-7 transfers, CPR and LBR were significantly lower than for Day-5 (CPR: OR 0.26, 95% CI 0.19-0.35, I2: 76.2%, 16 studies, 2799 and 34 442 transfers at Day-7 and Day-5, respectively; LBR: OR 0.23, 95% CI 0.16-0.33, I2: 76.3%, 12 studies, 2687 and 31 630 transfers at Day-7 and Day-5, respectively) and Day-6 blastocysts (CPR: OR 0.38, 95% CI 0.31-0.48, I2: 54.4%, 16 studies, 2799 and 28 563 transfers at Day-7 and Day-6, respectively; LBR: OR 0.37, 95% CI 0.28-0.49, I2: 60.2%, 12 studies, 2687 and 26 687 transfers at Day-7 and Day-6, respectively). Similarly, IR and OPR were significantly lower in the Day-7 group than in the Day-5 or Day-6 groups, while MR was higher compared with Day-5 blastocysts (OR 1.54, 95% CI 1.04-2.30, I2: 51.1%, 14 studies, 685 and 18 609 pregnancies at Day-7 and Day-5, respectively). When considering only PGT-A euploid blastocysts, CPR and LBR remained significantly lower in the Day-7 group compared with Day-5 (CPR: OR 0.21, 95% CI 0.14-0.33, I2: 58.0%, 7 studies, 365 and 7064 transfers at Day-7 and Day-5, respectively; LBR: OR 0.21, 95% CI 0.17-0.28, I2: 0%, 6 studies, 364 and 5924 transfers at Day-7 and Day-5, respectively) and Day-6 (CPR: OR 0.36, 95% CI 0.28-0.46, I2: 40.8%, 7 studies, 365 and 4617 transfers at Day-7 and Day-6, respectively; LBR: OR 0.36, 95% CI 0.28-0.46, I2: 0%, 6 studies, 364 and 3782 transfers at Day-7 and Day-6, respectively), and MR was higher than Day-5 (OR 2.78, 95% CI 1.57-4.89, I2: 32.4%, 6 studies, 95 and 4018 pregnancies at Day-7 and Day-5, respectively). Euploid rates were also significantly reduced for Day-7 blastocysts compared with Day-5 and Day-6. Data on perinatal outcomes were limited but overall reassuring. The pooled analyses revealed low to high heterogeneity across studies. WIDER IMPLICATIONS: Despite lower success rates, including for euploid embryos, Day-7 blastocysts may still contribute to cumulative live birth rates, notably in poor-prognosis patients. Prospective studies are needed to better assess perinatal and long-term outcomes. REGISTRATION NUMBER: PROSPERO (CRD420251114251).

来源:Hum Reprod Update,查看原文。版权归原作者所有。

引用

  1. Firmin J, Ducreux B, Saidessalam H, et al. Clinical outcomes of Day-7 blastocysts: a systematic review and meta-analysis. Hum Reprod Update. 2026. PMID: 42484399. doi:10.1093/humupd/dmag017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。